Published in Br Med J (Clin Res Ed) on January 16, 1982
Neurologic complications of cardiovascular diseases. J Natl Med Assoc (1989) 0.75
Digoxin toxicity presenting as encephalopathy. Postgrad Med J (1996) 0.75
Non-cardiac symptoms of digitalis intoxication. Am Heart J (1972) 1.31
Letter: Concentration of digoxin in choroid plexus. Lancet (1973) 1.07
Three per second spike-wave in digitalis toxicity. Report of a case. Arch Neurol (1971) 0.93
Study of serum digoxin status in digitoxicity by radioimmunoassay. Am Heart J (1980) 0.93
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
White-coat hypertension as a cause of cardiovascular dysfunction. Lancet (1996) 4.68
Impact of a policy of direct admission to a coronary care unit on use of thrombolytic treatment. Br Heart J (1989) 4.62
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. Br Heart J (1985) 2.92
Analysis of the pressor dose response. Clin Pharmacol Ther (1982) 2.44
Effects of prostaglandins, theophylline, and cholera exotoxin upon transmucosal water and electrolyte movement in the canine jejunum. Gastroenterology (1971) 2.39
Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers. Clin Pharmacol Ther (1981) 2.36
Cardiac troponin T. Lancet (1993) 2.13
Small bowel morphology in experimental canine cholera. A light and electron microscopic study. Lab Invest (1970) 2.12
A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol (1982) 2.06
Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Clin Pharmacol Ther (1999) 2.06
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet (2002) 2.00
Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol (2000) 1.96
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res (1996) 1.95
Nifedipine GITS. Lancet (1993) 1.94
Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol (1983) 1.89
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85
The genetic determination of left ventricular mass in healthy adults. Eur Heart J (2003) 1.77
Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a non-invasive marker. Br Heart J (1988) 1.75
Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J (1998) 1.71
Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J (1999) 1.64
Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem (1995) 1.58
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol (1994) 1.58
Aluminium toxicity during regular haemodialysis. Br Med J (1978) 1.54
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation (1997) 1.47
Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol (1985) 1.46
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol (2012) 1.46
Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) (2000) 1.44
Standard operating procedure for the collection of fresh frozen tissue samples. Eur J Cancer (2007) 1.43
The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene (1995) 1.43
Effects of nadolol on arrhythmias during laparoscopy performed under general anaesthesia. Br J Anaesth (1988) 1.41
The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol (1986) 1.41
Atrophy of villi with hypertrophy and hyperplasia of Paneth cells in isolated (thiry-Vella) ileal loops in rabbits. Light-microscopic studies. Gastroenterology (1975) 1.41
Assessment by general practitioners of suitability of thrombolysis in patients with suspected acute myocardial infarction. Br Heart J (1993) 1.40
Chemotherapy for colorectal cancer. J R Soc Med (2000) 1.40
Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther (1978) 1.40
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment? Br J Cancer (1989) 1.39
Cytotoxic-loaded albumin microspheres: a novel approach to regional chemotherapy. Br J Surg (1988) 1.36
Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer (1996) 1.33
Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet (1992) 1.33
Pseudohyperkalaemia. Br Med J (Clin Res Ed) (1985) 1.32
Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood (1992) 1.27
Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation (1993) 1.26
The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res (1996) 1.25
Plasmapheresis in the treatment of dialysis encephalopathy. Lancet (1978) 1.23
A pragmatic approach to the pressor dose-response as an index of vascular reactivity and adrenoceptor function in man. Br J Clin Pharmacol (1987) 1.22
Evidence for postjunctional vascular alpha 2-adrenoceptors in peripheral vascular regulation in man. Clin Sci (Lond) (1983) 1.22
Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J (1992) 1.22
How reproducible is bilateral forearm plethysmography? Br J Clin Pharmacol (1998) 1.21
The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. Br J Clin Pharmacol (1985) 1.20
Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction. Lancet (1990) 1.20
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res (1986) 1.19
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res (1993) 1.18
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol (2005) 1.17
The pressor dose-response in clinical cardiovascular pharmacology. Br J Clin Pharmacol (1987) 1.17
Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J Clin Oncol (1998) 1.16
Preliminary experience with a hospital blood pressure follow up clinic with nurse practitioner assessment and microprocessor based data retrieval. Br Med J (Clin Res Ed) (1984) 1.16
Kinetic-dynamic relations and individual responses to enalapril. Hypertension (1990) 1.16
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol (1996) 1.14
Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1998) 1.14
A prospective randomized trial of tocainide in patients following myocardial infarction. Am Heart J (1980) 1.11
Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation (1996) 1.11
The use of BRL26921 (APSAC) as fibrinolytic therapy in acute myocardial infarction. Eur Heart J (1985) 1.11
Relation between extent of coronary artery disease and severity of hyperlipoproteinaemia. Br Heart J (1975) 1.10
Effect of age on the responsiveness of vascular alpha-adrenoceptors in man. J Cardiovasc Pharmacol (1982) 1.10
Home delivery: chemotherapy and pizza? BMJ (2001) 1.09
Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res (2001) 1.09
Wide variation in the use of thrombolytic therapy among junior doctors in south and central Scotland. Health Bull (Edinb) (1996) 1.09
Lymphoid and epithelial markers in small cell anaplastic thyroid tumours. J Clin Pathol (1985) 1.09
Leucocyte ascorbic acid levels after acute myocardial infarction. Br Heart J (1972) 1.08
Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases. Br J Surg (1990) 1.07
The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour. Br J Cancer (1991) 1.07
Haemodynamic effects of prenalterol in patients with coronary heart disease. Br Heart J (1980) 1.07
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther (2001) 1.06
The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol (1992) 1.06
Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer (1988) 1.05
The TERT variant rs2736100 is associated with colorectal cancer risk. Br J Cancer (2012) 1.05
Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer (1991) 1.04
Nifedipine: individual responses and concentration-effect relationships. Hypertension (1988) 1.03
Hypercholesterolaemia in treated hypertensives: a controlled trial of intensive dietary advice. J Hypertens Suppl (1989) 1.03
The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension. Br J Clin Pharmacol (1986) 1.03
Mistyping of the human angiotensin-converting enzyme gene polymorphism: frequency, causes and possible methods to avoid errors in typing. J Mol Endocrinol (1996) 1.03
Hepatocellular carcinoma. Ann Oncol (2001) 1.03
Neural network and regression predictions of 5-year survival after colon carcinoma treatment. Cancer (2001) 1.03
Experimental central nervous system phaeohyphomycosis following intranasal inoculation of Xylohypha bantiana in cortisone-treated mice. Mycopathologia (1987) 1.02
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Control Release (1999) 1.02
Arteriovenous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate, and the effect of angiotensin II. Nucl Med Commun (1987) 1.02
The epidemiology of thyroid carcinoma. Crit Rev Oncog (1993) 1.02
Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension (1995) 1.01
Vascular and aldosterone responses to angiotensin II in normal humans: effects of nicardipine. J Cardiovasc Pharmacol (1986) 1.00
Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol (1987) 0.99
Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastases. Br J Cancer (1991) 0.99
ABC of sports medicine. Sudden death in sport. BMJ (1994) 0.99
Alcoholic ketoacidosis: a case report. Scott Med J (1987) 0.99
Establishing a national tissue bank for surgically harvested cancer tissue. Br J Surg (2004) 0.99
Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol (1998) 0.98
Familial pattern of corticosteroids and their metabolism in adult human subjects--the Scottish Adult Twin Study. J Clin Endocrinol Metab (1999) 0.98
Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer (1994) 0.98